Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the...
/PRNewswire/ -- Leaderboard Branding, a Fingerpaint company, the fast-growing global naming and branding firm that delivers strategic insights and world-class...
Chicago, Illinois (PRWEB) June 06, 2022 -- On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present
– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate –– 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles –– 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event –– 83% Reported Grade 3 Adverse Events of Special Intere...
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2...